Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent

Registration

Registration

NCT02660047

Acronym

MAGNA VICTORIA

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE4

Masking

QUADRUPLE

Status

COMPLETED

Enrollment

51

Start

2015-08

Primary completion

2018-03-09

Lead sponsor

Leiden University Medical Center

Conditions

Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver

Interventions

DRUG:Liraglutide; DRUG:Liraglutide - Placebo

Results posted

FALSE

Registered primary outcomes

• Stroke volume [0 and 26 weeks]
• Ejection Fraction [0 and 26 weeks]
• Cardiac output [0 and 26 weeks]
• Cardiac index [0 and 26 weeks]
• Peak ejection rate [0 and 26 weeks]
• Early peak filling rate [0 and 26 weeks]
• Early deceleration peak [0 and 26 weeks]
• Atrial peak filling rate [0 and 26 weeks]
• Early deceleration peak / Atrial peak filling rate (E/A ratio) [0 and 26 weeks]
• Peak mitral annulus longitudinal motion [0 and 26 weeks]
• Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion) [0 and 26 weeks]